eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
three other countries � spain, czech republic, and slovakia � had also been warned by the eu, but devised sufficient air management plans within the requested time frame.
.